Physician profile
Theodore G Pettle
NPI 1003102211
$1,409.79
in general payments reported to CMS, 2019-2025
14 companies · $48.36 in 2025
The $48.36 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14.20 · 2020: $32.48 · 2021: $131 · 2022: $312 · 2023: $786 · 2024: $85.82 · 2025: $48.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $920.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $662.23 | 2022-2025 | |
| Janssen Biotech, INC. | $202.11 | 2021-2023 | Stelara, Simponi Aria, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $159.27 | 2020-2023 | Trulance |
| Boston Scientific Corporation | $93.57 | 2023 | Exalt Model D |
| Gilead Sciences, INC. | $47.16 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $42.00 | 2023 | Brilinta |
| Mallinckrodt Hospital Products INC. | $40.56 | 2023 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $34.66 | 2022 | |
| Redhill Biopharma INC. | $34.25 | 2022-2023 | Talicia |
| Olympus America INC. | $28.94 | 2025 | Endoclot Phs |
| Takeda Pharmaceuticals U.S.A., INC. | $22.10 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.25 | 2024 | Voquezna |
| Allergan, INC. | $14.20 | 2019 | |
| Sirtex Medical INC | $12.49 | 2023 | Sir-Spheres Microspheres |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Pettle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.